Table 9.
Comparison of adverse events between the two groups
| Parameters | Mirena group (n = 81) | Mirena combined with Leuprorelin group (n = 63) | χ2 | P |
|---|---|---|---|---|
| Vaginal spotting | 12 (14.81%) | 5 (7.94%) | 1.610 | 0.204 |
| Amenorrhea | 16 (19.75%) | 15 (23.81%) | 0.345 | 0.557 |
| Breast tenderness | 2 (2.47%) | 0 (0.00%) | 0.290 | 0.590 |
| Low estrogen | 4 (4.94%) | 6 (9.52%) | 0.553 | 0.457 |